{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:59:40Z","timestamp":1790135980660,"version":"4.0.1"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Melinta Therapeutics, Inc.","award":["3000301634"],"award-info":[{"award-number":["3000301634"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>\n                    The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant\n                    <jats:italic>Enterobacteriaceae<\/jats:italic>\n                    (CRE) infections remains unknown. This was a multicenter, retrospective cohort study of adults with CRE infections who received ceftazidime-avibactam or meropenem-vaborbactam for \u226572\u2009hours from February 2015 to October 2018. Patients with a localized urinary tract infection and repeat study drug exposures after the first episode were excluded.\n                  <\/jats:p>","DOI":"10.1128\/aac.02313-19","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:29:34Z","timestamp":1582183774000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":159,"title":["Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant\n                    <i>Enterobacteriaceae<\/i>\n                    Infections"],"prefix":"10.1128","volume":"64","author":[{"given":"Renee","family":"Ackley","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Atrium Health, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danya","family":"Roshdy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Atrium Health, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Meredith","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Atrium Health, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Minor","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, AdventHealth, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Evaluation, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald A.","family":"Capraro","sequence":"additional","affiliation":[{"name":"Carolinas Pathology, Atrium Health Clinical Microbiology Laboratory, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Polk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Atrium Health, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2019. Antibiotic resistance threats in the United States 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02349-16"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02636-14"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.11.009"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv050"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.01.016"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2015.298"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx438"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy576"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00537-17"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01551-18"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02497-17"},{"key":"e_1_3_2_20_2","volume-title":"Avycaz (ceftazidime\/avibactam)","author":"Allergan USA, Inc","year":"2019","unstructured":"Allergan USA, Inc. 2019. Avycaz (ceftazidime\/avibactam). Prescribing information. Allergan USA Inc., Irvine, CA."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01694-17"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01969-17"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-020-0710-9"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1131"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01413-16"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00888-17"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_3_2_28_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing, 26th ed (M100S). Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"26"},{"key":"e_1_3_2_29_2","volume-title":"Tygacil (tigecycline). Prescribing information","author":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer, Inc","year":"2020","unstructured":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer, Inc. 2020. Tygacil (tigecycline). Prescribing information. Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., Philadelphia, PA."},{"key":"e_1_3_2_30_2","volume-title":"Vabomere (meropenem and vaborbactam)","author":"Melinta Therapeutics","year":"2018","unstructured":"Melinta Therapeutics. 2018. Vabomere (meropenem and vaborbactam). Prescribing information. Melinta Therapeutics, Lincolnshire, IL."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02313-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02313-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:45:49Z","timestamp":1645461949000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02313-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.02313-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02313-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02313-19"}}